ZECOTEK PHOTONICS INC.

Interim Consolidated Financial Statements

(Expressed in Canadian Dollars)

(Unaudited)

April 30, 2015

ZECOTEK PHOTONICS INC.

Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
April 30, 2014

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditors have not performed a review of these condensed interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

ZECOTEK PHOTONICS INC.

Consolidated Statements of Financial Position
(Expressed in Canadian dollars)
(Unaudited)

	April 30, 2015	July 31, 2014
Assets		
Current assets:		
Cash and cash equivalents	$ 1,377,890	$ 615,265
Trade receivables	76,076	23,068
Goods and services taxes recoverable	25,690	20,244
Advances to employees (note 12(c) and 12(d))	275,032	137,554
Prepaid expenses	692,802	139,802
Total current assets	2,447,490	935,933
Non-current assets:		
Restricted investments (note 3(c))	56,553	54,936
Deposits	47,409	35,348
Property and equipment (note 4)	67,593	69,991
Patent costs (note 5)	70,532	89,498
Total non-current assets	242,087	249,773
Total assets	$ 2,689,577	$ 1,185,706
Liabilities and Shareholders' Deficiency		
Current liabilities:		
Trade and other payables (notes 8(c), 9 and 12)	$ 3,948,120	$ 4,017,741
Customer deposits	2,991,553	-
	6,939,673	4,017,741
Shareholders' deficiency:		
Share capital (note 6)	56,668,666	53,139,204
Contributed surplus	13,804,798	12,861,372
Deficit	(74,550,122)	(68,760,803)
Accumulated other comprehensive income	(173,438)	(71,808)
Total shareholders' deficiency	(4,250,096)	(2,832,035)
Nature of business and going concern uncertainty (note 1)		
Commitments and contingencies (note 8)		
Subsequent events (note 15)		
Total liabilities and shareholders' deficiency	$ 2,689,577	$ 1,185,706

See accompanying notes to consolidated financial statements.

Approved on behalf of the Board:

"Faouzi Zerrouk" Director *"David Toyoda"* Director

ZECOTEK PHOTONICS INC.

Consolidated Statements of Comprehensive Loss
(Expressed in Canadian dollars)
(Unaudited)
For the three months and nine months ended April 30, 2015 and 2014

	Three Months		Nine Months	
	2015	2014	2015	2014
Revenue	70,149	14,284	243,680	63,812
Expenses				
Operating, general and administrative	928,038	1,588,238	4,785,559	3,535,907
Research and development	378,214	391,161	1,247,440	1,021,730
	1,306,252	1,979,399	6,032,999	4,557,637
Net loss	(1,236,103)	(1,965,115)	(5,789,319)	(4,493,825)
Other comprehensive gain (loss)				
Exchange gain (loss) on translation of foreign operations	76,703	(7,549)	(101,630)	(194,589)
Net comprehensive loss	(1,159,400)	(1,972,664)	(5,890,949)	(4,688,414)
Net loss per common share – basic and diluted	$(0.01)	$(0.02)	$(0.05)	$(0.05)
Weighted average number of common shares outstanding - basic and diluted	112,258,554	96,658,625	107,016,096	92,795,212

ZECOTEK PHOTONICS INC.

Consolidated Statements of Changes in Equity (Deficiency)
(Expressed in Canadian Dollars)
(Unaudited)
Nine months ended April 30, 2015 and 2014

	Number of Shares	Share capital	Contributed surplus	Accumulated other comprehensive income	Deficit	Total shareholders equity (deficiency)
As at August 1, 2013	82,598,166	$ 43,693,611	$ 13,824,087	$ 131,240	$ (60,307,692)	$ (2,658,754)
Share issuance on private placements (note 6(b)):						
Issuance of shares	5,966,938	3,460,824	-	-	-	3,460,824
Issue costs	-	(274,051)	-	-	-	(274,051)
Issuance of warrants	-	(206,878)	206,878	-	-	-
Issuance of finder's warrants	-	(38,984)	38,984	-	-	-
Exercise of warrants	5,030,046	2,600,782	-	-	-	2,600,782
Exercise of stock options	1,315,000	1,313,600	(506,200)	-	-	807,400
Comprehensive loss	-	-	-	(194,589)	(4,493,825)	(4,688,414)
Share based payment (note 6(b))	3,236,370	1,475,784	(1,475,784)	-	-	-
Stock-based compensation	-	-	415,802	-	-	415,802
As at April 30, 2014	98,146,520	$ 52,024,688	$ 12,503,767	$ (63,349)	$ (64,801,517)	$ (336,411)

	Number of Shares	Share capital	Contributed surplus	Accumulated other comprehensive income	Deficit	Total shareholders equity (deficiency)
As at August 1, 2014	99,018,341	$ 53,139,204	$ 12,861,372	$ (71,808)	$ (68,760,803)	$ (2,832,035)
Share issuance on private placements (note 6(b)):						
Issuance of shares	13,060,213	4,571,075	-	-	-	4,571,075
Issue costs	-	(432,041)	-	-	-	(432,041)
Issuance of warrants	-	(666,924)	666,924	-	-	-
Issuance of finder's warrants	-	(59,648)	59,648	-	-	-
Exercise of warrants	-	-	-	-	-	-
Exercise of stock options	180,000	117,000	(36,000)	-	-	81,000
Comprehensive loss	-	-	-	(101,630)	(5,789,319)	(5,890,949)
Stock-based compensation	-	-	252,854	-	-	252,854
As at April 30, 2015	112,258,554	$ 56,668,666	$ 13,804,798	$ (173,438)	$ (74,550,122)	$ (4,250,096)

See accompanying notes to consolidated financial statements.

ZECOTEK PHOTONICS INC.

Consolidated Statements of Cash Flows
(Expressed in Canadian dollars)
(Unaudited)
For the three and nine months ended April 30, 2015 and 2014

	Three Months		Nine months	
	2015	**2014**	**2015**	**2014**
Cash flows provided by (used in):				
Operating Activities:				
Net loss for the period	$ (1,236,103)	$ (1,965,115)	$ (5,789,319)	$ (4,493,825)
Adjustments for items not involving cash:				
Amortization of property and equipment	8,942	11,942	22,458	33,046
Amortization of patent costs	7,690	7,373	22,512	21,544
Foreign exchange (gain) / loss	33,234	(6,978)	(67,992)	(55,811)
Stock-based compensation	3,359	174,978	252,854	415,802
	(1,182,878)	(1,777,800)	(5,559,487)	(4,079,244)
Changes in non-cash working capital:				
Trade receivables	18,039	173	(53,008)	(722)
Goods and services taxes recoverable	(3,447)	(2,520)	(5,446)	(14,991)
Advances to employees	(57,155)	(74,555)	(137,478)	(39,734)
Prepaid expenses	(590,332)	(288,045)	(553,000)	(314,381)
Trade and other payables	(103,139)	12,619	(1,629)	(129,450)
Customer deposit	(83,480)	-	2,991,553	-
Net cash flows used in operating activities	(2,002,392)	(2,130,128)	(3,318,495)	(4,578,522)
Investing Activity:				
Acquisition of property and equipment	(13,863)	(12,457)	(18,283)	(19,329)
Deposits	(10,033)	-	(10,531)	-
Net cash flows used in investing activity	(23,896)	(12,457)	(28,814)	(19,329)
Financing Activities:				
Proceeds from shares and units issued	-	2,873,129	4,652,075	6,869,006
Share subscriptions received	-	21,500	-	21,500
Share issuance costs	-	-	(432,041)	(274,051)
Net cash flows from/(used in) financing activities	-	2,894,629	4,220,034	6,616,455
Effects of exchange rate changes on cash	82,160	-	(110,100)	-
Increase (decrease) in cash and cash equivalents	(1,944,128)	752,044	762,625	2,018,604
Cash and cash equivalents, beginning of period	3,322,018	1,477,667	615,265	211,107
Cash and cash equivalents, end of period	$ 1,377,890	$ 2,229,711	$ 1,377,890	$ 2,229,711

See accompanying notes to consolidated financial statements.

1. Nature of business and going concern uncertainty:

(a) Nature of business:

Zecotek Photonics Inc. (the "Company") was incorporated on November 25, 1983 under the laws of the Province of British Columbia, Canada. The head office for the Company is located at: Unit 1120 - 21331 Gordon Way, Richmond, BC, Canada.

The activities of the Company are focused on the creation of advanced materials and integrated optoelectronic devices for high resolution medical imaging, optical precision surgery and biopharmaceutical research.

The Company has one significant wholly owned subsidiaries, Zecotek Photonics Singapore Pte. Ltd. which holds 100% ownership interests in Zecotek Display Systems Pte. Ltd., Zecotek Imaging Systems Pte. Ltd. and Zecotek Laser Systems Pte. Ltd. These subsidiaries all have principal activities of research and development (and eventual exploitation) of medical laser technologies. Zecotek Imaging Systems Pte. Ltd. holds a 100% ownership interest in Zecotek Imaging Systems (Malaysia) SDN BHD ("ZISM") which was incorporated on June 24, 2008 with the same principal activity.

(b) Going concern uncertainty:

The Company's ability to continue to operate and meet its obligations as they come due is dependent upon the ability of the Company to obtain further equity financing as necessary, retain the support of its principal shareholders, and to successfully bring its technologies to market and achieve future profitable operations. The ultimate outcomes of these matters cannot presently be determined because they are contingent on future events.

These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which presumes that the Company will be able to realize assets and discharge its liabilities in the normal course of business for the foreseeable future. As at April 30, 2015, the Company had very limited operating revenue, a working capital deficiency of $4,457,989, shareholders' deficiency of $4,215,902 and negative operating cash flows of $3,318,836. The Company's current revenue is not sufficient to sustain operations. These factors, among others, create substantial doubt as to the ability of the Company to continue as a going concern.

Management of the Company believes that it will be successful in meeting its business objectives and raising additional funds, and that the going concern assumption remains appropriate.

These financial statements do not give effect to adjustments, if any, which would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and liquidate its liabilities in other than the normal course of business and at amounts which may differ from those shown in the financial statements.

2. Basis of presentation:

(a) Statement of compliance:

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), applicable to the preparation of interim financial statements, including International Accounting Standard 34 *Interim Financial Reporting* ("IAS34") as issued by the International Accounting Standards Board ("IASB"). Our accounting policies outlined in note 3 have been applied in preparing our consolidated financial statements as at and for the quarters ended April 30, 2015 and 2014.

These consolidated financial statements were reviewed by the Audit Committee and approved and authorized to be issued by the Board of Directors on June 30, 2015.

(b) Basis of measurement:

These consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments which are recorded at fair value.

(c) Significant judgments and estimates:

The preparation of these consolidated financial statements requires management to make judgments, estimates, and assumptions that affect application of accounting policies and the reported amounts of assets, liabilities at the date of the year-end consolidated financial statements and reported amounts of revenue and expenses during the reporting period.

Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates. Significant items subject to such estimates and assumptions include the recoverable amount of equipment and intangible assets, future economic benefits of the collaboration costs, and assumptions used in determining the fair value of options and warrants.

Significant judgments made by management in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the financial statements includes the application of the going concern assumption and the determination of related parties.

3. Significant accounting policies:

(a) Basis of consolidation:

These consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company as at April 30, 2015 and 2014 and the results of all its subsidiaries for the quarters then ended. Subsidiaries are all those entities which the Company controls, where control is defined as having the power to govern the financial and operating policies and exposure to variable returns. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases. The accounting policies of subsidiaries are changed when necessary to align them with the policies adopted by the Company. Inter-entity transactions, balances and unrealized gains on consolidated group are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of impairment of the asset transferred. The Company's accounting policies are applied consistently throughout the organization.

(b) Cash and cash equivalents:

Cash and cash equivalents consists of cash on hand, balances on deposit with banks and highly liquid market investments with original terms of maturity of less than ninety days at time of acquisition, intended for use in current operations.

(c) Restricted investments:

Restricted investments are short-term investments pledged as security or otherwise subject to restricted liquidity, and are recorded at fair market value.

(d) Property and equipment:

Property and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. The cost of property and equipment comprises its purchase price and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is provided primarily on the declining balance basis at the following annual rates:

Asset	Basis	Rate
Equipment	Declining balance	20% to 33%
Furniture	Declining balance	20% to 30%
Vehicle	Declining balance	30%
Leasehold improvements	Straight-line	3 years

Depreciation rates and salvage values are reviewed annually.

3. Significant accounting policies (continued):

(e) Patents and trademarks:

Product registration costs related to efforts by the Company to acquire legal protections for its proprietary products, such as trademarks and patents, are capitalized if the Company believes that obtaining the trademark or patent, and recovery of the costs from future related revenues is reasonably assured, otherwise the costs are expensed. Capitalized costs are amortized on a straight-line basis over 5 to 20 years. The amortization period is determined based on the anticipated duration of legal protection, an assessment of the period of time over which the Company may be able to generate revenues from the related product, and expected obsolescence.

(f) Research and development expenditures:

Research costs are expensed in the year as incurred.

Development costs include all expenditures considered directly attributable to efforts by the Company to develop, and bring to commercial production, a new product. Such amounts are charged as an expense in the period incurred except in circumstances where the product or process is clearly defined and the costs attributable thereto can be identified, the technical feasibility has been established, management has indicated its intention to produce and market the product, the future market is clearly defined, adequate resources are available, and recovery of development costs can reasonably be regarded as assured, in which case such costs are capitalized. For the quarters ended April 30, 2015 and 2014, no costs have been capitalized.

(g) Impairment:

(*i*) Non-financial assets:

The carrying amounts of non-current assets, including property and equipment, and patent costs are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized in net loss if the carrying amount of an asset exceeds its estimated recoverable amount. The recoverable amount of an asset is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

An impairment loss is reversed if there has been a significant change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of amortization, if no impairment loss had been recognized.

3. Significant accounting policies (continued):

(g) Impairment (continued):

(*ii*) Financial assets:

Financial assets not carried at fair value through earnings are assessed for impairment at each reporting date. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset. For financial assets measured at amortized cost, the impairment loss is the difference between the carrying amount and the present value of the estimated future cash flows, discounted at the original effective interest rate. If impairment has occurred, the carrying amount of the asset is reduced, with the amount of the loss recognized in earnings.

(h) Foreign currency translation:

(*i*) Functional and presentation currency:

Items included in the financial statements of each of the Company's entities are measured using the currency of the primary economic environment in which the entity operates ("the functional currency"). The consolidated financial statements are presented in Canadian dollar, which is the functional and presentation currency of the Company.

(*ii*) Translation of accounts of foreign subsidiaries:

On consolidation, the financial statements of foreign operations are translated into Canadian dollar using exchange rate at the end of reporting period for the financial position and average exchange rate over the reporting period for the income statement. Foreign currency translation differences are recognized in other comprehensive income.

(*iii*) Transactions in foreign currency:

Transactions made in a foreign currency are translated using the currency rate at the time of the translation. Monetary assets and liabilities in foreign currency are measured at the currency rate at the closing date and the translation differences are charged in profit and loss.

(i) Provisions:

A provision is recognized on the basis of a legal or constructive obligation arising from a past event, if there is a more likely than not outflow of resources and the amount can be estimated reliably. Where the effect of discounting is material, the expected future cash flows associated with a provision are discounted at a pre-tax rate that reflects current market assessments of the time value of money. The unwinding of the discount is recognized as a finance cost.

3. Significant accounting policies (continued):

(j) Employee compensation costs:

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. The Company recognizes a liability when we have a present legal or constructive obligation to pay the amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

(k) Financial instruments:

Financial assets and liabilities are measured at fair value upon their initial recognition. All financial instruments have been classified into one of the following five categories: (1) held-to-maturity; (2) loans and receivables; (3) other financial liabilities; (4) available-for-sale financial assets; and (5) fair value through profit or loss.

Subsequent measurement is based on either fair value or amortized cost, depending upon the classification. Financial assets at fair value through profit or loss are measured at fair value with changes in the fair value recognized in net income. Available-for-sale financial instruments are measured at fair value with changes in fair value recorded in other comprehensive income until the investment is derecognized or impaired at which time the amounts would be recorded in net income. For other financial liability, subsequent adjustments to expected cash flows are recorded if and when they occur through adjustments to the related expense.

The Company's financial instruments are classified as follows:

- Cash and cash equivalents, and restricted investments are classified as loans and receivable, which as measured at amortized cost using the effective interest method.
- Trade receivables, advances to employees and refundable deposits are classified as loans and receivables and are measured at amortized cost using the effective interest method.
- Trade and other payables, finance lease liability and loans payable are classified as other financial liabilities and are measured at amortized cost using the effective interest method.

(l) Stock-based compensation:

The Company grants stock options to employees, directors, officers and consultants pursuant to the stock option plan described in note 6(e). The fair value method of accounting for stock-based compensation transactions is used. Management uses judgment to determine the inputs to the Black-Scholes option pricing model including the expected plan lives, underlying share price volatility and forfeiture rates. The fair value of stock options is generally estimated at the date of grant using the Black-Scholes Option Pricing Model. For graded vested share options, IFRS 2 requires the use of the attribution method, which requires that the company treat each installment as a separate share option grant with a different fair value.

3. Significant accounting policies (continued):

(l) Stock-based compensation (continued):

The fair value of stock-based payments to non-employees is based on fair value of the goods or services received, when these can be measured reliably. In the event that no reliable measurement can be made, the fair value of the options granted will be used.

(m) Warrants:

Proceeds from issuances by the Company of units consisting of shares and warrants are allocated on a pro-rata basis as determined by the fair value of each element. The fair value of the warrants is estimated using the Black-Scholes option pricing model. In circumstances where finder's warrants are issued coincidentally with a unit offering, the finder's warrants are valued using the Black-Scholes option pricing model.

(n) Share issue costs:

Professional, agent and regulatory fees, as well as, other costs directly attributable to specific financing transactions are reported as deferred financing costs until the transactions are completed, if successful completion is considered reasonably assured. Share issue costs are charged to capital stock when the related shares are issued. Costs relating to financing transactions that are not completed or for which completion is considered unlikely, are charged to net loss.

(o) Income taxes:

Income tax expense comprises current and deferred tax. Income tax expense is recognized in net earnings except to the extent that it relates to items recognized directly in equity, in which case it is recognized directly in equity.

Current income tax is the expected tax payable (recoverable) on the taxable income for the period, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable (recoverable) in respect of previous years.

Deferred income tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable income. Deferred income tax liabilities are generally recognized for all taxable temporary differences. Deferred income tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable income will be available against which those deductible temporary differences can be utilized.

The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable income will be available to allow all or part of the asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rate that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

(p) Loss per share:

Basic loss per share is calculated using the weighted average number of shares outstanding during the quarter. The Company uses the treasury stock method to compute the dilutive effect of options, warrants and similar instruments. Under this method the dilutive effect on loss per share is recognized based on the use of proceeds that could be obtained upon exercise of such options, warrants and similar instruments. It assumes that the proceeds would be used to purchase common shares at the average market price during the period. This calculation generally produces an anti-dilutive effect for loss years.

(q) Revenue recognition:

Revenue is recognized when the Company's product is shipped, the title is transferred to the customer and collection of the amount billed is considered reasonably assured.

(r) Government assistance:

Government grants are recognized when there is reasonable assurance that the Company has complied with the conditions of the grant. Such grants are accounted for as a reduction of the related expense or asset, or as income, as appropriate. When circumstances arise that indicate repayment is likely or when there is a formal demand for repayment, government grants previously recorded as a reduction of related expenditures or expenses is recorded as a liability in the year the condition for repayment arises.

(s) Changes in accounting policies:

(*i*) Consolidated Financial Statements

Effective August 1, 2013, The Company adopted IFRS 10, *Consolidated Financial Statements* ("IFRS 10"). IFRS 10 establishes principles for the presentation and preparation of consolidated financial statements when an entity controls one or more other entities. The adoption of IFRS 10 did not have any impact on the consolidated financial statements.

(*ii*) Joint Arrangements

Effective August 1, 2013, The Company adopted IFRS 11, *Joint Arrangements* ("IFRS 11"). IFRS 11 supersedes IAS 31, *Interest in Joint Ventures*, and SIC-13, *Jointly Controlled Entities-Non-Monetary Contributions by Ventures*. IFRS 11 requires that joint ventures be accounted for using the equity method of accounting and eliminates the need for proportionate consolidation.

The Company was not impacted by the adoption of IFRS 11.

3. Significant accounting policies (continued):

(s) Changes in accounting policies (continued):

(*iii*) Disclosure of Interests in Other Entities

Effective August 1, 2013, the Company adopted IFRS 12, *Disclosure of Interests in Other Entities* ("IFRS 12"). IFRS 12 is a new and comprehensive standard on disclosure requirements for all forms of interests in other entities, including subsidiaries, joint arrangements, associates and unconsolidated structured entities. The adoption of IFRS 12 has resulted in additional disclosures within the consolidated financial statements.

(*iv*) Fair Value Measurements

Effective August 1, 2013, the Company adopted IFRS 13, *Fair Value Measurements* ("IFRS 13"). IFRS 13 provides new guidance on fair value measurement and disclosure requirements. The adoption of IFRS 13 resulted in minor changes in disclosure within Note 10, but did not have a significant impact on the consolidated financial statements.

(*v*) Financial Instruments

Effective August 1, 2013, the Company adopted amendments to IFRS 7, *Financial Instruments Disclosures* ("Amendments to IFRS 7"), which amend the disclosure requirements in IFRS 7 to require information about all recognized financial instruments that are offset in accordance with IAS 32.The adoption of Amendments to IFRS 7 did not have any impact on the consolidated financial statements.

(v*i*) IFRIC 21 - Levies

Effective August 1, 2014, the Company adopted IFRIC 21, *Levies*. The adoption of IFRIC 21 did not have a material impact on the financial statements.

(*vii*) IAS 32 Amendments, Offsetting Financial Assets and Liabilities

Effective August 1, 2014, the Company adopted the amendments to IAS 32, *Offsetting Financial Assets and Financial Liabilities* in its financial statements. The adoption did not have a material impact on the financial statements.

(*viii*) IAS 36 Amendments - Recoverable Amount Disclosures for Non-Financial Assets

Effective August 1, 2014, the Company adopted amendments to IAS 36, *Recoverable Amount Disclosures for Non-Financial Assets* ("Amendments to IAS 36"). The adoption of the amendments did not have a material impact on the financial statements.

(ix) Annual Improvements to IFRS (2010 - 2012) and (2011 - 2014) cycles:

Effective August 1, 2014, the Company adopted the IASB issued narrow - scope amendments to a total of nine standards as part of its annual improvements process. The IASB uses the annual improvements process to make non-urgent but necessary amendments to IFRS. The adoption of these amendments did not have a material impact on the financial statements.

3. Significant accounting policies (continued):

(t) New standards and interpretations not yet adopted:

The following standards and interpretations, that have been issued but are not yet effective as of January 31, 2015, have not been applied in preparing the financial statements.

(i) IFRS 9 - *Financial Instruments*:

In November 2009 the IASB issued IFRS 9, *Financial Instruments* (“IFRS 9 (2009)”), and in October 2010, the IASB published amendments to IFRS 9 (“IFRS 9 (2010)”).

In November 2013, the IASB issued a new general hedge accounting standard, which forms part of IFRS 9, *Financial Instruments* (2013). The new standard removes the January 1, 2015 effective date of IFRS 9. The new mandatory effective date will be determined once the classification and measurement and impairment phases of IFRS 9 are finalized.

The mandatory effective date is not yet determined; however, early adoption of the new standard is still permitted. The Company does not intend to adopt IFRS 9 (2009), IFRS 9 (2010) or IFRS 9 (2013) in its financial statements for the annual period beginning on August 1, 2014.

(*ii*) IFRS 15 - Revenue from Contracts with Customers:

In May 2014, the IASB issued IFRS 15 - *Revenue from Contracts with Customers*, which replaces IAS 18 - *Revenue*, IAS 11 - *Construction Contracts* and other interpretive guidance associated with revenue recognition. The standard contains a single model that applies to contracts with customers and two approaches to recognizing revenue: at a point in time or over time. The model features a contract-based five-step analysis of transactions to determine whether, how much and when revenue is recognized. New estimates and judgmental thresholds have been introduced, which may affect the amount and/or timing of revenue recognized. The new standard is effective for fiscal years ending on or after December 31, 2017 and is available for early adoption.

The Company intends to adopt IFRS 15 in its financial statements for the annual period beginning on August 1, 2018. The extent of the impact of adoption of the standard has not yet been determined..

3. Significant accounting policies (continued):

(t) New standards and interpretations not yet adopted (continued):

(*iii*) Clarification of Acceptable Methods of Depreciation and Amortization (Amendments to IAS 16 and IAS 38):

On May 12, 2014 the IASB issued amendments to IAS 16 *Property, Plant and Equipment* and IAS 38 *Intangible Assets*.

The amendments made to IAS 16 explicitly state that revenue-based method of depreciation cannot be used for property, plant and equipment. This is because such methods reflect factors other than the consumption of economic benefits embodied in the asset.

The amendments in IAS 38 introduce a rebuttable presumption that the use of revenue-based amortization methods for intangible assets is inappropriate. This presumption could be overcome only when revenue and consumption of the economic benefits of the intangible asset are highly correlated or when the intangible asset is expressed as a measure of revenue.

The Company intends to adopt the amendments to IAS 16 and IAS 38 in its financial statements for the annual period beginning on August 1, 2016. The Company does not expect the amendments to have a significant impact on the financial statements

(Expressed in Canadian dollars)

4. Property and equipment:

	Equipment	Furniture	Leasehold improvements	Vehicle	Total
August 1, 2013	$196,245	$ 48,125	$ 399,847	$ 64,062	$ 708,279
Additions	19,329	-	-	-	19,329
Effect of movements in exchange rates	10,269	3,277	32,602	5,223	51,371
April 30, 2014	$ 225,843	$ 51,402	$ 432,449	$ 69,285	$ 778,979

	Equipment	Furniture	Leasehold improvements	Vehicle	Total
August 1, 2014	$231,949	$ 51,424	$ 432,746	$ 69,333	$ 785,452
Additions	18,283	-	-	-	18,283
Effect of movements in exchange rates	7,063	1,516	20,017	3,207	31,803
April 30, 2015	$ 257,295	$ 52,940	$ 452,763	$ 72,540	$ 835,538

(Expressed in Canadian dollars)

4. Property and equipment (continued):

Accumulated depreciation:

	Equipment	Furniture	Leasehold improvements	Vehicle	Total
August 1, 2013	168,212	38,297	358,337	57,658	622,504
Depreciation	7,184	1,513	22,395	1,493	32,585
Effect of movements in exchange rates	9,909	2,754	30,197	4,766	47,626
April 30, 2014	$ 185,305	$ 42,564	$ 410,929	$ 63,917	$ 702,715

	Equipment	Furniture	Leasehold improvements	Vehicle	Total
August 1, 2014	188,871	43,101	419,009	64,480	715,461
Depreciation	9,919	1,252	10,189	1,093	22,453
Effect of movements in exchange rates	5,751	1,274	19,974	3,032	30,031
April 30, 2015	$ 204,541	$ 45,627	$ 449,172	$ 68,605	$ 767,945

	Equipment	Furniture	Leasehold improvements	Vehicle	Total
Carrying amount:					
April 30, 2014	$ 40,538	$ 8,838	$ 21,520	$ 5,368	$ 76,264
April 30, 2015	52,754	7,313	3,591	3,935	67,593

(Expressed in Canadian dollars)

5. Patent costs:

Costs:	
August 1, 2013	$ 274,815
Effect of movements in exchanges rates	19,425
April 30, 2014	$ 294,240
Costs:	
August 1, 2014	$ 294,419
Effect of movements in exchanges rates	11,927
April 30, 2015	$ 306,346
Accumulated depreciation:	
August 1, 2013	$ 164,317
Depreciation	21,544
Effect of movements in exchange rates	11,586
April 30, 2014	$ 197,447
Accumulated depreciation:	
August 1, 2014	$ 204,921
Depreciation	22,511
Effect of movements in exchange rates	8,382
April 30, 2015	$ 235,814
Carrying amount:	
April 30, 2014	$ 96,793
April 30, 2015	70,532

6. Share capital:

(a) Authorized:

The authorized share capital of the Company is an unlimited number of common voting shares with no par value.

(b) Issued and outstanding common shares:

On November 28, 2014, the Company completed the second tranche of the share subscription agreements for the financing announced October 23, 2014. Under the agreements, the subscribers purchased 5,003,073 units of the Company at a price of $0.35 per unit, for gross proceeds of $1,751,076. Each unit consists of one common share and one share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of $0.50 per share for a period of 24 months after the date of the private placement. Pursuant the closing of the second tranche of the financing, the Company paid finder's fees and agents commission of $121,473 and issued non-transferable finder's warrants to purchase 347,063 Common Shares at $0.50 per share before November 28, 2016. All shares and warrants are subject to a four-month hold period expiring on March 29, 2015.

On November 19, 2014, the Company extended (the "Warrant Extension") by 18 months the term of outstanding share purchase warrants (the "Warrants") exercisable at a price of $0.50 per common share for 472,222 common shares of the Company, which were issued pursuant to a private placement which closed on December 3, 2012. All of the Warrants were originally exercisable for two years from the date of issuance, subject to acceleration, such that if the closing price of the common shares of the Company on the TSX Venture Exchange (the "Exchange") is equal to or greater than $1.00 for a period of 10 consecutive trading days (the "Trading Target"), the Warrants will expire on the date that is 30 days after the date the Trading Target is met.

On November 12, 2014, the Company completed the first tranche of the share subscription agreements for the financing announced October 23, 2014. Under the agreements, the subscribers purchased 8,057,140 units of the Company at a price of $0.35 per unit, for gross proceeds of $2,819,999. Each unit consists of one common share and one share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of $0.50 per share for a period of 24 months after the date of the private placement. Pursuant the first tranche of the financing, the Company paid finder's fees and agents commission of $197,400 and issued non-transferable finder's warrants to purchase an aggregate of 555,999 Common Shares at $0.50 per share before November 12, 2016. All shares and warrants are subject to a four-month hold period expiring on March 13, 2015.

On September 4, 2013, the Company completed the share subscription agreements for the financing announced August 20, 2013. Under the agreements, the subscribers purchased 5,966,938 units of the Company at a price of $0.58 per unit, for gross proceeds of $3,460,824. Each unit consists of one common share and one half of one share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise

(Expressed in Canadian dollars)

6. Share capital (continued):

(b) Issued and outstanding common shares (continued):

price of $0.75 per share for a period of 24 months after the date of the private placement. The warrant's exercise period will automatically accelerate to 30 days if the common shares of the Company trade above $1.25 for a period of 10 consecutive trading days. The estimated fair value of the common share purchase warrants granted was determined to be $347,197 using the Black-Scholes option pricing model (note 6 (d)).

The Company paid finder's fees in the amount of $234,040 and 403,516 non-transferable finder's warrants for the financing. Each finder's warrant entitles the holder to purchase one common share at a price of $0.75 for a period of 24 months after the date that the private placements closed. All shares and warrants are to be subject to a four-month hold period. The estimated fair value of the finders' warrants granted was determined to be $69,405 using the Black-Scholes option pricing model (note 6(d)). Legal and other costs amounted to $99,205.

(c) Common share purchase warrants:

	Number of warrants	Weighted average exercise price
Balance, July 31, 2013	12,130,999	0.53
Warrants granted	2,983,469	0.75
Warrants exercised	(4,914,779)	(0.52)
Balance, July 31, 2014	10,199,689	0.59
Warrants granted	13,060,213	0.75
Warrants expired	(5,029,499)	(0.55)
Balance, April 30, 2015	18,230,403	$ 0.54

Common share purchase warrants outstanding at April 30, 2015 are summarized as follows:

Exercise price	Number of warrants	Weighted average remaining life (years)
$ 0.50	15,246,934	1.05
$ 0.75	2,983,469	0.35
	18,230,403	0.94

(Expressed in Canadian dollars)

6. Share capital (continued):

(d) Finder's warrants:

	Number of warrants	Weighted average exercise price
Balance, July 31, 2013	782,480	0.50
Warrants granted	403,516	0.75
Warrants exercised	(407,088)	(0.50)
Balance, July 31, 2014	778,908	0.63
Warrants granted	903,062	0.50
Warrants expired	(342,687)	(0.50)
Balance, April 30, 2015	1,339,283	$ 0.58

Finder's warrants outstanding at April 30, 2015 are summarized as follows:

Exercise price	Number of warrants	Weighted average remaining life (years)
$ 0.50	935,767	1.08
$ 0.75	403,516	0.35
	1,339,283	0.89

The fair value of finder's and common share purchase warrants has been estimated at the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:

2015:	
Annualized stock volatility	57.50%
Risk-free interest rate	1.02%
Expected option/warrant life	2.0 years
Dividend payments	0.0%
2014:	
Annualized stock volatility	44.44%
Risk-free interest rate	1.29%
Expected option/warrant life	2.0 years
Dividend payments	0.0%

(Expressed in Canadian dollars)

6. Share capital (continued):

(e) Stock options:

On December 30, 2014, the Board of Directors approved a new stock option plan. Under the plan, the Company may grant options to purchase common shares in the Company to employees, directors, officers, and consultants of the Company. The exercise price of the options is to be determined by the Board of Directors but generally will be equal to or greater than the market price of the shares at the grant date. Options will generally vest according to the following schedule:

25%	on grant date
25%	3 months after grant date
25%	6 months after grant date
25%	9 months after grant date

As of April 30, 2015, the Company has reserved 21,451,000 common shares for issuance of stock options to employees, directors, officers and consultants of the Company of which 7,106,000 were available for future issuance.

Stock option transactions and numbers outstanding are summarized below:

	Number of options	Weighted average exercise price
Balance, July 31, 2013	14,525,000	0.59
Options granted	4,485,000	0.77
Options exercised	(1,895,000)	(0.56)
Options expired	(1,820,000)	(1.60)
Balance, July 31, 2014	15,295,000	0.64
Options granted	-	-
Options expired	(770,000)	(0.71)
Options exercised	(180,000)	(0.45)
Balance, April 30, 2015	14,345,000	$ 0.64

(Expressed in Canadian dollars)

6. Share capital (continued):

(e) Stock options (continued):

Options outstanding at April 30, 2015 are summarized as follows:

Exercise price	Number of options	Number of options exercisable	Weighted average remaining life (years)
$ 0.43	1,350,000	1,350,000	3.04
$ 0.45	1,515,000	1,515,000	2.18
$ 0.57	1,135,000	1,135,000	1.76
$ 0.64	3,685,000	3,685,000	0.72
$ 0.65	2,175,000	2,175,000	1.40
$ 0.70	1,785,000	1,785,000	4.02
$ 0.82	2,700,000	2,700,000	3.73
	14,345,000	14,345,000	2.25

During the Nine months ended April 30, 2015, the Company recorded $252,854 (2014 - $415,802) of compensation expense representing the fair value of the options vesting during the quarter with a corresponding increase to contributed surplus.

7. Capital disclosures:

The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The Company includes shareholders' equity and long-term debt in the definition of capital.

The Company manages its capital structure and makes adjustments to it in light of economic conditions. To maintain or adjust the capital structure, the Company may attempt to issue new shares, issue new debt, acquire or dispose of assets or undertake other activities as deemed appropriate under the specific circumstances.

The Company is not subject to externally imposed capital requirements and the Company's overall strategy with respect to capital risk management remains unchanged from the year ended July 31, 2014.

(Expressed in Canadian dollars)

8. Commitments and contingencies:

(a) Commitments:

Years ending July 31	Rental leases	Research contracts	Total
2015 (balance of year)	$ 45,785	$ 65,602	$ 111,387
2016	90,368	65,602	155,970
2017	80,279	41,000	121,279
	$ 216,432	$ 172,204	$ 388,636

Rental leases relate to the Company and its subsidiaries commitments under operating leases for rental of properties. Research contract commitments relate to contractual obligations entered into by the Company and its subsidiaries for research and development.

(b) Litigation:

Zecotek Imaging Systems Pte Ltd., a wholly owned subsidiary had filed legal action in United States Federal District Court in Los Angeles against defendants Saint-Gobain Corporation and Philips for infringement of Zecotek's U.S. Patent Number 7,132,060. The patent covers the substances and chemical formulations used to grow lutetium fine silicate ("LFS") scintillation crystals which are characterized by their combined high light yield and ultra-fast decay times and are typically used in medical scanning devices. The lawsuit alleged that Saint-Gobain's LYSO crystals infringe Zecotek's patent, and that Philips infringes by using those crystals in the PET scanners it sells. On December 22, 2014 Zecotek Imaging Systems Pte. Ltd. reached a settlement with both Philips and Saint Gobain. While terms of the settlement remain confidential, Zecotek and Philips have identified areas of cooperation in the field of medical imaging and look forward to establishing a meaningful business relationship.

(c) Compensation waivers:

In March of 2011, the Company entered into agreements with certain of its consultants, directors and employees (the "individuals").

Under these agreements, the individuals waived the salaries and fees owed to them totaling $1,113,455 in favor of bonus payments of the same amounts, which are to be paid upon certain triggering events, including a sale of substantially all of the assets of the Company, or the shares of the Company, commercialization of any of the technologies of the Company, a public listing of shares of a subsidiary of the Company, or cash inflows exceeding $3,000,000 in any three month period.

The liability for this compensation will remain included in accounts payable and accrued liabilities until such time as it can be determined that the liability is legally extinguished or that the Company's obligation to pay is unlikely.

8. Commitments and contingencies (continued):

(d) Intellectual property:

On June 26, 2013, Zecotek Photonics Inc. entered into a joint collaboration agreement with Invention Development Management Company, LLC ("IDMC") for collaboration on intellectual property strategy, including the sourcing, development and monetization of new inventions related to photonics. The agreement will also provide the Company with the opportunity to licence intellectual properties and technologies from IDMC's own portfolio of photonics related inventions and patents created with its network of inventors.

In consideration, the Company:

(*i*) issued IDMC 5,393,951 common shares over a period of 6 months;

(*ii*) agreed to pay IDMC 5% of the gross proceed on any settlement of or damage award in any of the Company's patent infringement litigation involving U.S. patent number 7.132.060 (or any of its related family members) commenced before date of the Agreement; and

(*iii*) if a settlement includes any licensing royalty settlement component ("Licensing Component") for a period of 60 months commencing on receipt of first licensing royalty settlement payment, pay IDMC 5% of such Licensing Component.

9. Government grants:

The Company has received grants from the Government of Singapore - Economic Development Board ("EDB") and the Government of Malaysia - Industrial Development Authority ("MIDA"). During the 2009 year, the Company received Singapore dollars $1,554,778 (Canadian dollars $1,232,162) and recorded this as a reduction in expenditures and expenses as management believed there was reasonable assurance that the amounts would not have to be repaid. The EDB grant is contingently repayable should the Company not meet certain requirements in respect to local employment, expenditures and production. As at July 31, 2010, it was determined that certain of these conditions were not met in respect to the EDB grant.

The Company received correspondence from the EDB in August 2010 in which the EDB required repayment of cumulative grants received by the Company in the amount of Singapore dollars $1,554,778 (Canadian dollars $1,420,756), referring to the Company not meeting all original conditions of the grant. The amount has been recognized as a liability, under accounts payable. The Company disputes the repayment requirement, believes the EDB had previously waived or postponed some conditions and is in discussion with the EDB seeking to eliminate the amount owing by the Company.

In May 2012, EDB requested the Company to provide a fresh update on all the grant conditions to better evaluate the Company's appeal for changes to the grant conditions in order to reduce the repayment to EDB. As at the end of April 30, 2015, EDB had not yet completed reviewing the information provided by the Company.

10. Financial instruments:

(a) Fair value:

The Company's financial instruments consist of cash and cash equivalents, investments, trade receivables, advances to employees, restricted investments, trade and other payables, and loans payable. The fair values of cash and cash equivalents, trade receivable, advances to employees, trade and other payables, and loans payable approximate carrying value because of the short-term nature of these instruments. The interest rates applied to the obligations under capital lease are not considered to be materially different from market rates, thus the carrying value of obligations under capital lease approximate fair value. The carrying value of short-term investments equal their fair values as they are classified as held for trading.

Fair value measurements recognized in the balance sheet must be categorized in accordance with the following levels:

(*i*) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;

(*ii*) Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e., derived from prices);

(*iii*) Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company categorized the fair value measurement of its short-term investments in Level 1 as they are primarily derived directly from reference to quoted (unadjusted) prices in active markets.

(b) Financial risk management:

The Company primarily has exposure to credit risk, foreign exchange rate risk, interest rate risk, and liquidity risk.

(*i*) Credit risk:

Financial instruments that potentially subject the Company to concentration of credit risks include cash and restricted short-term investments. The Company places its cash and restricted short-term investments with high credit quality financial institutions. Short-term investments are generally held in fixed rate securities. Concentration of credit risks with respect to receivables is limited.

(*ii*) Foreign exchange risk:

Foreign exchange risk is the risk that the fair value or future cash flow of a financial instrument will fluctuate because of changes in foreign exchange rate.

The Company has significant operations in Singapore, which gives rise to significant foreign currency translation risks from fluctuations and volatility of foreign exchange rate between the Canadian dollar and the Singapore dollar ("SGD"). A significant change in the currency exchange rates between the SGD relative to the Canadian dollar could have

(Expressed in Canadian dollars)

10. Financial instruments (continued):

(*ii*) Foreign exchange risk (continued):

an effect on the Company's financial performance, financial position and cash flows. The Company does not use derivative instruments to reduce its exposure to exchange rate risk.

The Company's financial instruments subject to exchange rate risk are listed below.

SGD		April 30, 2015		April 30, 2014
Financial assets:				
Cash and cash equivalents	$	143,104	$	652,697
Trade receivables		-		13,502
Restricted investments		40,000		40,000
Financial liabilities:				
Trade and other payables		(3,269,100)		(3,306,398)
Gross financial position exposure	$	(3,085,996)	$	(2,600,199)
Canadian dollar equivalents	$	(2,819,984)	$	(2,269,453)

The following are exchange rates applied to presentation of the consolidated financial statements for the periods ended April 30, 2015 and 2014:

SGD		April 30, 2015		April 30, 2014
Canadian dollar				
Average rate	$	1.12	$	1.18
Closing rate		1.09		1.15

A 10% strengthening (weakening) of the Canadian dollar against SGD would have increased (decreased) deficiency and comprehensive loss by the amounts below. This analysis assumes all other variables, such as interest rates, remain constant.

SGD		April 30, 2015		April 30, 2014
Canadian dollar	$	(281,999)	$	(226,945)

(Expressed in Canadian dollars)

10. Financial instruments (continued):

(*iii*) Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Restricted investments with fixed interest rates include guaranteed investment certificates with original maturities of greater than three months expose the Company to interest rate risk. The Company does not use financial instruments to mitigate this interest rate risk.

(*iv*) Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company currently settles its financial obligations using cash and cash equivalents. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Trade and other payables have contractual maturity of 6 months or less.

11. Segmented information:

The Company has principal operations in Canada and Singapore (Asia) and is organized into three sales geographic areas consisting of Asia, Europe, and North America. Reporting information by geographic area is as follows:

April 30, 2015	Asia	Europe	America	Total
Revenue	$ 234,355	$ 2,924	$ 6,401	$ 243,680
Property and equipment	63,629	-	3,964	67,593
Patent costs	70,444	-	88	70,532

April 30, 2014	Asia	Europe	America	Total
Revenue	$ 63,812	$ -	$ -	$ 63,812
Property and equipment	70,928	-	5,336	76,264
Patent costs	93,049	-	3,744	96,793

(Expressed in Canadian dollars)

12. Related party transactions:

The Company undertook the following transactions with related parties. These transactions were measured at the exchange amounts which are the amounts of consideration established and agreed upon by the related parties.

(a) The Company incurred $22,900 (2014 - $5,843) in legal fees to Boughton Law Corporation, legal counsel to the Company, for legal services rendered during the quarter. A director of the Company is an Associate Counsel of Boughton Law Corporation. At April 30, 2015, $16,547 (2014 - $nil) was outstanding and included in trade and other payables.

(b) During the quarter, the Company incurred salaries of $50,938 (2014 - $48,574) for the Executive Vice President, Operations. The advances to the Executive Vice President, Operations amount to $1,392 as at April 30, 2015 (2014 - $18,439).

(c) The Company incurred fees of $45,000 (2014 - $45,000) during the quarter for consulting services provided by the chief financial officer. At April 30, 2015, $26,750 (2014 - $26,750) of the fees was unpaid and included in trade and other payables.

(d) During the quarter, the Company incurred salaries and allowances of $50,082 (2014 - $47,757) for the President and CEO and fees of $118,033 (2014 - $149,501) for consulting services to a company controlled by the President and CEO. The advances to the President and CEO, amount to $269,984 as at April 30, 2015 (2014 - $44,536).

(e) The Company incurred fees of of $19,500 (2014 - $19,500) during the quarter for directors' services. At April 30, 2015, $93,000 (2014 - $84,500) was unpaid and included in trade and other payables.

(f) The Company incurred fees of $30,000 (2014 - $30,000) during the quarter for accounting and related services to a company controlled by the Corporate Secretary.

(g) The following table summarizes the compensation of the Company's key management:

	April 30 2015	April 30, 2014
Short term employee salary and benefits	$ 947,752	$ 966,000
Termination benefits	629,938	597,500

(Expressed in Canadian dollars)

13. General and administrative expenses:

The following table presents the Company's general and administrative expenses according to their nature:

	April 30 2015	April 30 2014
Professional fees	$ 3,325,578	$ 1,874,941
Insurance	18,822	18,861
Marketing and promotion	44,631	147,849
Office	122,055	152,271
Rent	151,704	136,142
Salaries and benefits	719,241	602,152
Travel	232,229	311,748
Foreign exchange loss	(67,992)	(91,073)
Amortization of property and equipment	19,034	30,860
Stock-based compensation	220,257	352,156
Total	$ 4,785,559	$ 3,535,907

14. Research and development expenses:

The following table presents the Company's research and development expenses according to their nature:

	April 30 2015	April 30 2014
Consulting fees	$ 438,263	$ 336,410
Overhead costs	37,422	13,359
Supplies	228,297	139,432
Salaries and benefits	111,248	139,336
Patent costs	373,678	305,814
Amortization of property and equipment	3,424	2,186
Amortization of patent costs	22,512	21,544
Stock-based compensation	32,596	63,649
Total	$ 1,247,440	$ 1,021,730

15. Subsequent events:

(a) 32,705 finder's warrants expired on June 7, 2015.

(b) On June 11, 2015; 8,750 finder's warrants were exercised at an average rate of $0.50 for total cash proceeds of $4,375. On June 15, 2015; 8,000 finder's warrants were exercised at an average rate of $0.50 for total cash proceeds of $4,000.